索引于
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 研究圣经
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • 普罗奎斯特传票
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 米亚尔
  • 欧洲酒吧
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Thiopurine Methyltransferase Genotype Testing in Paediatric Patients in South Australia. A Retrospective Audit into Prescribing Practices.

Mahindroo S, Fletcher J, Hissaria P, Hakendorf P, Nicholson S.

Background: Thiopurines are used to treat a number of medical conditions including inflammatory bowel disease, acute lymphoblastic leukemia and severe eczema in children. Pre prescription identification of variant alleles helps reduce thiopurine related adverse events. The aim of the study was to explore the clinical utility of TPMT genotyping in a paediatric population in South Australia, specifically the uptake of testing and whether the results are guiding appropriate dosing of thiopurines in keeping with current established international guidelines. Methods: A retrospective audit was conducted reviewing all patients below the age of 18 years who underwent TPMT genotyping in South Australia during the 10-year period between January 2004 and January 2014. Data regarding demographics and prescribing practices was collected from the medical records of 260 paediatric patients. Results: Paediatric gastroenterologists requested 67% of the TPMT genotypes performed. Loss of function alleles were confirmed in almost 9% of cases. There were positive correlations between adverse events and whether the test was used correctly (p 0.011) and with subspecialty unit (p<0.001). Oncology recorded the largest percentage of adverse events 63.5% whilst only comprising 16.5% of the total dataset. Conclusion: The safest prescribing practice in all groups of patients is to ensure the TPMT gentyope is performed prior to administration and dosing is guided by the results and established guidelines.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证